Dr.
Dr Geoffrey Lindeman
Oncology
- 🇬🇧
- GP consultation
- Annual physical exam
- Vaccination administration
- Minor procedure (skin)
About Dr Geoffrey Lindeman
Dr Geoffrey Lindeman is a clinician-scientist. Their primary areas of research include immunotherapy, fundamental biology, personalised medicine, cell signalling, cell death, epigenetics, and transcriptional regulation. They study molecular regulators of normal mammary gland development and cancer. Their work focuses on understanding how mammary stem cells and their progeny contribute to the mammary epithelial cell hierarchy and breast cancer. This led to the discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers. Their laboratory uses patient-derived xenograft (PDX) and tumour organoid models to test promising anti-cancer agents.
"Evidence-based care tailored to each patient — taking the time to explain options and shared decisions."
Credentials & verification
Medical license
Organización Médica Colegial de España (OMC) ·
#-367358
Valid until 2028-12-31
Verify with issuerBoard certification
European Board of Oncology
#EB-D1EDFE3E
Renewal due 2038
Verify with issuerMalpractice cover
HDI Global
5,000,000 EUR
Valid until 2026-12-31
No claims on file
Education & training
-
2017–2023
MD · Medicine and Surgery
Universitat de València
-
2023–2027
Residency · Oncology
UAB Barcelona
-
2027–2028
Fellowship · Subspecialty training
Mayo Clinic, US
Career & appointments
-
2027-09–2028-08
Junior consultant
Universitat de València Teaching Hospital — Oncology
Procedures & conditions
| Procedure | Code | Lifetime volume |
|---|---|---|
| GP consultation | 99213 |
173 |
| Annual physical exam | 99395 |
3,019 |
| Vaccination administration | 90471 |
891 |
| Minor procedure (skin) | 17110 |
1,108 |
Patient reviews
"Very thorough first visit — explained every step. Booking was easy and the staff were welcoming."
"Took time to listen and reviewed all my previous results. I would absolutely recommend."
"Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent."
Recognition & press
Awards
- Top-rated Oncology — — EuroClinics Patient Choice · 2025 regional
Society memberships
- WONCA Europe — Family Doctors — Member · since 2028
- national college of family doctors — Member · since 2028
- European Union of Medical Specialists (UEMS) — Member · since 2028
Your consultation, step by step
- 1 Choose a slot
- 2 Brief pre-consult form
- 3 Consultation
- 4 Follow-up note & plan
Services & pricing
New patient consultation (60m)
Follow-up consultation (30m)
Vaccination administration
Minor procedure (skin)
Research & publications
h-index: 7 · i10: 16
Selected publications
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.9854/euroclin.2025.0 · cited by 61
-
European registry analysis of Oncology outcomes
DOI: 10.1549/euroclin.2024.1 · cited by 119
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.2721/euroclin.2023.2 · cited by 57
Show full research record
Additional publications
-
European registry analysis of Oncology outcomes
Invited talks
- Practical updates in Oncology · European Annual Congress (Oncology) · Vienna · 2024
- Single-centre experience in Oncology · National Society Meeting · · 2023
Articles by Dr Geoffrey Lindeman
Frequently asked
01. Do you accept new patients?
Dr Geoffrey Lindeman is currently accepting new patients. Use the booking module to choose a slot.
02. Which languages can I be seen in?
Consultations are available in English.
03. Is the consultation in-person or online?
Most services are offered both in-clinic and via telemedicine. Each service card above marks its modalities.
04. Do you accept my insurance?
Please use the booking flow to enter your insurance — we verify and confirm before your slot.
05. What is the cancellation policy?
Free cancellation up to 24 hours before your slot. Last-minute cancellations may incur a small administrative fee.
06. How is my health data protected?
All records are stored on EU servers, field-level encrypted, and GDPR compliant. Data is never shared with third parties without your explicit consent.